<SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-GB"> <FONT size=4>加拿大卫生部和</FONT></SPAN><FONT size=4><SPAN lang=EN-GB style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; mso-font-kerning: 0pt; mso-ansi-language: EN-GB">Hoffmann-La Roche Limited </SPAN><SPAN lang=EN-GB style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-GB">(</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-GB">罗氏公司<SPAN lang=EN-GB>)</SPAN>共同发布了致医生和消费者的信,警示与骁悉(</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">吗替麦考酚酯</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-GB">)相关的单纯红细胞再生障碍性贫血(</SPAN><SPAN lang=EN-GB style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; mso-font-kerning: 0pt; mso-ansi-language: EN-GB">PRCA</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-GB">)风险。骁悉是一种免疫抑制剂,用于预防接受同种异体肾移植、心脏或肝脏移植的急性器官排斥反应。信中称,在联合使用骁悉和其他免疫抑制剂治疗的患者中,有报道发生<SPAN lang=EN-GB><FONT size=4>PRCA</FONT></SPAN>。</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">吗替麦考酚酯</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-GB">导致<SPAN lang=EN-GB><FONT size=4>PRCA</FONT></SPAN>的机理尚不清楚。在一些病例中,随着骁悉剂量的减少或中止,<SPAN lang=EN-GB><FONT size=4>PRCA</FONT></SPAN>发生可逆性改变。然而,对于器官移植患者,减少免疫抑制剂的使用可能使移植器官遭受排斥风险。</SPAN></FONT> |